002001:SZSEZhejiang NHU Company Ltd. Analysis
Data as of 2026-03-17 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Zhejiang NHU is trading well above its 20‑day, 50‑day and 200‑day moving averages at CNY 35.28, with a bullish MACD crossover and rising volume supporting a short‑term upside momentum. However, the DCF‑derived fair value of roughly CNY 19.7 suggests the market may be overpaying, while the trailing PE of about 15 is markedly below the industry average of 26, indicating a valuation disconnect. The company posts strong profitability (gross margin ~46%, operating margin ~38%) and solid cash generation, with cash far exceeding debt, and it pays a modest dividend yield of 1.88% on a low payout ratio, which appears sustainable. Overall, the stock reflects a blend of growth and value characteristics but faces heightened volatility (≈50% 30‑day) and regulatory exposure typical of the specialty‑generic pharma sector.
Market Outlook
Short Term
< 1 yearKey Factors
- Bullish MACD and increasing volume support near‑term momentum
- Current price near the upper end of the 20‑day SMA band and close to resistance
- DCF fair value gap raises concern of short‑term pullback
Medium Term
1–3 yearsKey Factors
- PE well below industry average indicating relative undervaluation
- Strong cash flow and low debt‑to‑equity provide financial flexibility
- Sustainable dividend yield adds income appeal
Long Term
> 3 yearsKey Factors
- High ROE (~24%) and consistent profit margins signal durable competitive advantage
- Diversified product portfolio across nutrition, flavor, polymer and API segments reduces concentration risk
- Low beta and robust balance sheet mitigate market volatility over the long horizon
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.